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Abstract
Background: There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in
the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information
Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. In this report we describe
the design of the study, the methods used and the characteristics of the participants.
Methods: Participants were selected from existing prospective multicenter and single-center European studies.
Inclusion criteria were having normal cognition (NC) or a diagnosis of mild cognitive impairment (MCI) or AD-type
dementia at baseline, age above 50 years, known amyloid-beta (Aβ) status, availability of cognitive test results and
at least two of the following materials: plasma, DNA, magnetic resonance imaging (MRI) or cerebrospinal fluid (CSF).
Targeted and untargeted metabolomic and proteomic analyses were performed in plasma, and targeted and untargeted
proteomics were performed in CSF. Genome-wide SNP genotyping, next-generation sequencing and methylation
profiling were conducted in DNA. Visual rating and volumetric measures were assessed on MRI. Baseline characteristics
were analyzed using ANOVA or chi-square, rate of decline analyzed by linear mixed modeling.
Results: We included 1221 individuals (NC n = 492, MCI n = 527, AD-type dementia n= 202) with a mean age of 67.9
(SD 8.3) years. The percentage Aβ+ was 26% in the NC, 58% in the MCI, and 87% in the AD-type dementia groups.
Plasma samples were available for 1189 (97%) subjects, DNA samples for 929 (76%) subjects, MRI scans for 862 (71%)
subjects and CSF samples for 767 (63%) subjects. For 759 (62%) individuals, clinical follow-up data were available. In each
diagnostic group, the APOE ε4 allele was more frequent amongst Aβ+ individuals (p < 0.001). Only in MCI was there a
difference in baseline Mini Mental State Examination (MMSE) score between the A groups (p< 0.001). Aβ+ had a faster
rate of decline on the MMSE during follow-up in the NC (p < 0.001) and MCI (p < 0.001) groups.
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Conclusions: The characteristics of this large cohort of elderly subjects at various cognitive stages confirm the central
roles of Aβ and APOE ε4 in AD pathogenesis. The results of the multimodal analyses will provide new insights into
underlying mechanisms and facilitate the discovery of new diagnostic and prognostic AD biomarkers. All researchers can
apply for access to the EMIF-AD MBD data by submitting a research proposal via the EMIF-AD Catalog.
Keywords: Alzheimer’s disease, Biomarkers, Multimodal, Proteomics, Genomics, Metabolomics, Plasma, Magnetic
resonance imaging, DNA, Cerebrospinal fluid,
Background
Over the last decade great progress has been made in
diagnosing Alzheimer’s disease (AD) at an early disease
stage, including before the onset of dementia [1, 2]. The
biomarkers amyloid-beta (Aβ) and tau in cerebrospinal
fluid (CSF) or amyloid and tau load via positron emission
tomography (PET) have become indispensable in the AD
research field, especially as part of clinical trials for disease
modification and secondary prevention [3–6]. Nonethe-
less, a better understanding of the underlying patho-
physiological disease mechanisms as well as the discovery
of diagnostic and prognostic markers that are inexpensive
and minimally invasive to obtain would enhance the de-
velopment of therapeutic interventions.
Currently, CSF and PET biomarkers are commonly used
for the early diagnosis and prognosis of AD [7–9]. How-
ever PET imaging is fairly expensive and not universally
available and the procedure for obtaining a PET scan as
well as CSF data are relatively invasive. Given this, comple-
menting these highly specific biomarker modalities with
markers in more readily accessible biofluids would mark
an important step forward. Consequently, many initiatives
have been undertaken to discover and validate blood-based
biomarkers for AD pathology [10, 11], but so far results
have been limited, due to small sample sizes, single modal-
ity analyses or other methodological issues [12]. One crit-
ical issue so far has been the design (comparing individuals
with AD-type dementia with controls), which made the
studies unsuitable for discovery of markers for the preclin-
ical disease phase. To seek markers for the preclinical
phase, a more sensitive and gradual approach has been
proposed, described as the “endophenotype approach”
where discovery is predicted on a measure of pathology
[13]. Therefore, we designed the current study to enhance
blood-based biomarker discovery by performing a series of
omics techniques (e.g., proteomics, metabolomics, genom-
ics) in a large cohort across the AD clinical disease
spectrum, using an endophenotype approach.
This study was performed as a part of the European
Medical Information Framework for Alzheimer’s disease
(EMIF-AD; http://www.emif.eu). Funded through the In-
novative Medicines Initiative (IMI), the EMIF project
was established to facilitate the process of reusing and
combining existing healthcare data with a focus on two
therapeutic areas in the first instance: metabolic diseases
and AD. One of the main aims of the EMIF-AD project
is to accelerate the discovery of novel diagnostic and
prognostic biomarkers for AD and to unravel the under-
lying pathophysiological mechanisms, using existing data
and existing samples, that would otherwise be inaccess-
ible to research beyond the project teams responsible for
the collection. In this report, we will describe the set-up
of the EMIF-AD Multimodal Biomarker Discovery
(EMIF-AD MBD) study, the methods as well as the
characteristics of the included subjects. The results of
the single and multimodal analyses will be described in
future publications.
Methods
General outline
In the EMIF-AD MBD study we retrospectively combined
and reused clinical data, samples and scans that had already
been collected as part of existing prospective cohort studies.
We aimed to include a total of 1000 subjects across the
clinical AD spectrum: 400 subjects with normal cognition
(NC), 400 subjects with mild cognitive impairment (MCI)
and 200 subjects with mild AD-type dementia. To create a
balanced design in terms of progression and to enable
endophenotype designed biomarker studies, we intended to
include 50% Aβ-positive (Aβ+) individuals and 50%
Aβ-negative (Aβ–) individuals in the groups with NC and
MCI. To conduct multimodal analyses, we initially aimed
to include subjects who had material from MRI, plasma,
DNA and CSF. Later, we adjusted this to subjects with
material available in at least two of the modalities listed.
Selection of cohorts
We used the EMIF-AD Catalog (https://emif-catalo-
gue.eu), established as part of the objective of the EMIF
which seeks to enable the finding, assessment and
reutilization of preexisting data. The EMIF-AD Catalog
contains metadata about European AD cohorts, enabling
the selection of studies that included subjects who, in this
instance, met the following inclusion criteria: data on Aβ
status, measured in CSF or by amyloid positron emission
tomography (PET); age above 50 years at baseline; and
availability of MRI scans, plasma and DNA samples. We
identified 16 suitable cohorts. Two cohorts declined due
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to other research interests. Three cohorts were interested
to collaborate, but unable because of legal and/or ethical
restrictions, or unavailability of sufficient sample volumes.
The 11 selected cohorts included three multicenter stud-
ies—EDAR (n = 204) [14], PharmaCog (n = 147) [15] and
DESCRIPA (n = 29) [16]—and eight single centers: Ant-
werp (n = 149) [17], Amsterdam (n = 172) [18], Barcelona
Sant Pau (n = 45) [19], Barcelona IDIBAPS (n = 120) [20],
Leuven (n = 180) [21], San Sebastian GAP (n = 40) [22],
Gothenburg (n = 95) [23] and Lausanne (n = 40) [24]. Of
these 11 cohorts, DESCRIPA, EDAR, PharmaCog,
Amsterdam, Antwerp and Gothenburg were linked to
partners in the EMIF-AD, while the other five cohorts
participated as affiliated data providers (ADP). All cohorts
(e.g., partners and ADP) signed a material transfer
agreement. The ADP also agreed to the EMIF project
agreement. Study managers from each cohort selected the
subjects based on the following criteria: age above 50 years
at baseline; availability of Aβ status at baseline measured
in CSF or via PET; availability of neuropsychological and
clinical data; availability of at least two of the following ma-
terials: MRI scan, plasma sample, DNA samples or CSF
sample; and absence of neurological, psychiatric or som-
atic disorders that could cause cognitive impairment. The
local medical ethical committee in each center approved
the study. Subjects had already provided written informed
consent at the time of inclusion in the cohort for use of
data, samples and scans. Figure 1 shows a timeline of the
different events in establishing this cohort, from the
search in the EMIF Catalog to the wet-lab analyses.
Baseline diagnoses
In all cohorts, the definition for NC was a normal perform-
ance on neuropsychological assessment (within 1.5 SD of
the average for age, gender and education). Five cohorts
also used a score of 0 on the Clinical Dementia Rating
(CDR) [25] and a single cohort used a cutoff value < 3 on
the Global Deterioration Scale [26] to determine NC.
Diagnosis of MCI was made according to the criteria of
Petersen [27] in nine cohorts. Two cohorts used the Win-
blad et al. criteria [28] to diagnose MCI. All cohorts used
the National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association criteria (NINCDS-ADRDA) criteria
[29] to diagnose AD-type dementia. Additional file 1:
Table S1 presents the diagnostic criteria used per center.
Clinical data
All cohorts were asked to contribute available data on
demographics, clinical information, neuropsychological
testing and Aβ status, as presented in Table 1. Medication
use and comorbidities were classified into a number of
categories, for which we created dichotomous variables
(Table 1).
Cognitive data were collected in all cohorts. The cogni-
tive tests used varied across centers. Only the Mini Mental
State Examination (MMSE) was administered in all cen-
ters and was available for nearly all subjects (n = 1216).
We requested at least one test from the following cogni-
tive domains: memory, language, attention, executive
functioning and visuoconstruction [16]. For each cognitive
domain, we selected a primary test (Table 1). If the pre-
ferred tests were not available, we selected an alternative
priority test from the same cognitive domain. Additional
file 2: Table S2 provides an overview of the different tests
used for each cognitive domain. For each test, we re-
quested the raw scores and, if available, z-scores calculated
based on local normative data. If local normative data
were unavailable, we calculated z-scores based on
published normative data from healthy controls for that
test. Per cognitive domain, we combined z-scores which
Fig. 1 Timeline of events related to the EMIF-AD MBD study
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we used as a continuous variable, and we used a cutoff
value of z-score < − 1.5 to define abnormality.
Clinical data were harmonized, pooled and stored on
an online data platform using tranSMART [30], now
enriched for dementia research purposes through the
EMIF-AD project.
Plasma analyses
Initially, the minimum requested amount of plasma was
0.7 ml. If available, another 0.7 ml was requested to
conduct additional analyses in a subgroup of subjects. In
some cases, only 0.5 ml was available. Prior to the ana-
lyses, samples were checked visually for consistency and
volume. Results of analyses were also quality checked by
inspecting patterns of outliers, and excluding consistent
outliers across analyses. Analyses conducted on these
samples include: targeted analyses of plasma proteins
identified previously [31] and confirmed in at least one
replication study, a panel of complement proteins
nominated because of increasing evidence from genom-
ics of the role of innate immunity in AD and analysis of
plasma neurofilament light (NFL) chain; untargeted
proteomic analyses using aptamer capture approaches;
and untargeted and targeted metabolic analyses using a
883-metabolite panel for the targeted assay.
Genetic analyses
A total amount of 2.6 μg DNA or 1 ml whole blood, from
which DNA was to be extracted, was requested for the gen-
etic analyses. After performing routine quality checks on
extracted DNA (e.g., agarose gel electrophoresis, determin-
ation of A260/280 and A260/230 ratios, PicoGreen quanti-
fication), we performed three types of assessments on each
sample passing quality control: genome-wide SNP genotyp-
ing (Global Screening Array; Illumina, Inc.), genome-wide
DNA methylation profiling (Infinium MethylationEPIC
BeadChip; Illumina, Inc.) and whole exome sequencing.
CSF analyses
The requested amount of CSF to conduct all planned
analyses was 0.4 ml, which was used for untargeted prote-
omic and peptidomic analyses, and a number of targeted
analyses measuring concentrations of Aβ38, Aβ40, Aβ42,
Aβ42/40, YKL-40, NFL and neurogranin (Ng). Prior to the
analyses, CSF samples were checked visually for volume
and absence of blood contamination.
MRI analyses
MRI scans were assembled centrally, quality checked and
assessed visually by a single rater. T1-weighted and, when
available, FLAIR and/or T2*/SWI images were used for
qualitative visual rating, including medial temporal lobe
atrophy [32], global cortical atrophy [33], white matter
hyperintensities [34] and microbleeds (defined as small (<
10 mm) round foci of hypointense signal in brain
parenchyma). 3D T1 scans were uploaded to the Neurgrid
platform (https://neugrid4you.eu) [35] for storage and au-
tomated quantitative analyses. Volumetric analysis
included assessment of hippocampal and whole brain
volume and cortical thickness.
Amyloid classification
Aβ status was defined by the CSF Aβ42/40 of the central
analyses, using a cutoff value of < 0.061 to determine
Table 1 Clinical dataset
Demographics
Age
Gender
Years of education
Clinical information
Diagnosis
Medication use
Cardiovascular medication
Dementia medication
Hormonal medication
Psychopharmaceuticals
Other medication
Comorbidities
Cardiovascular disorders
Cardiovascular risk factors
Cerebrovascular disorders
Endocrine disorders
Neurological disorders
Other cardiac disorders
Psychiatric disorders
Somatic disorders
Family history of dementia
First-degree relatives
Second-degree relatives
Functional impairment rating
Neuropsychological tests
Memory, preferred test: AVLT
Language, preferred test: animal fluency
Attention, preferred test: Trail Making Test A
Executive functioning, preferred test: Trail Making Test B
Visuoconstruction, preferred test: Rey complex figure copy
Aβ measurea
CSF Aβ42 value and local cutoff point
Amyloid PET SUV and local cutoff point
aAt least one Aβ measure
Aβ amyloid-beta, AVLT Auditory Verbal Learning Test, CSF cerebrospinal fluid,
PET positron emission tomography, SUV standardized uptake value
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abnormality (n = 770). The cutoff value for the Aβ42/40
ratio was determined based on mixture model analyses
comparing the NC and AD groups in this dataset. When
no CSF was contributed for central analyses, the local
CSF Aβ42 value (n = 271) or the standardized uptake
value ratio (SUVR) on an amyloid PET scan (n = 180)
with local cutoff values to determine abnormality were
used (Additional file 3: Table S3).
Statistical analyses
Baseline characteristics were compared between groups
using ANOVA for continuous variables and chi-square for
categorical variables. General linear mixed models with
random intercepts and slopes by study were used to exam-
ine the influence of Aβ status on MMSE performance and
decline over time, adjusted for age, gender and years of
education. Missing values for APOE genotype (n = 12) and
years of education (n = 105) were imputed using regression
within study with at least two significant predictors (i.e.,
age, gender, MMSE, etc.). Statistical analyses were per-
formed using R Statistical Software (version 3.3.3) and SPSS
(version 24), with significance defined as p < 0.05.
Results
We initially sought to identify 1000 individuals with data
available in all modalities. However, because not all studies
could contribute data for all modalities, we included more
participants to meet the aimed number of individuals for
each modality. In total, 1221 subjects were included in the
study, with a mean age of 67.9 (SD 8.3) years. Six hundred
and sixty-seven (54%) were female and the average educa-
tion level was 11.7 (SD 4.1) years. At baseline, 492 (40%)
subjects had NC, 527 (43%) subjects had a diagnosis of
MCI and 202 (17%) subjects had a clinical diagnosis of
AD-type dementia. For 758 (62%) individuals there were
follow-up data available (e.g., at least a clinical diagnosis
or MMSE at follow-up): 217 (44%) NC subjects, 398
(76%) MCI subjects and 143 (71%) demented subjects.
The average follow-up time for all 758 individuals was 2.3
(SD 1.2) years. Per diagnostic groups, the average clinical
follow-up time was: NC 2.4 (SD 0.9) years, MCI 2.2 (SD
1.3) years and AD 2.2 (SD 1.4) years.
Table 2 presents the baseline characteristics of the
sample by Aβ status and by baseline diagnosis. In the
NC and MCI groups, the Aβ+ subjects were older than
the Aβ– subjects (NC, p = 0.002; MCI, p < 0.001). In all
diagnostic groups, Aβ+ subjects were more likely to be
an APOE ε4 carrier (all p < 0.001). In the MCI subjects
only, there was a difference in baseline MMSE score
between the Aβ groups (p = 0.001). Regarding cognitive
domains, we found differences in memory (p < 0.001)
and executive functioning (p = 0.042) z-scores in individ-
uals with MCI. In individuals with AD-type dementia we
found that Aβ+ individuals performed worse on an
executive functioning task (p = 0.013).
Table 3 presents the number of subjects per modality
by diagnostic category. Plasma samples were contrib-
uted for 1189 (97%) subjects, DNA for 929 (76%)
subjects, MRI scans for 862 (71%) subjects and CSF for
770 (63%) subjects. There were 482 (40%) subjects who
contributed material in all modalities. Of this sub-
sample, 89 (18%) subjects had NC, 318 (66%) subjects
MCI and 75 (16%) subjects had a diagnosis of AD-type
dementia at baseline.
Table 2 Baseline characteristics by clinical diagnosis and Aβ status
Normal cognition MCI AD-type dementia
Aβ– Aβ+ Aβ– Aβ+ Aβ– Aβ+
Total n n = 365 n = 127 n = 220 n = 307 n = 27 n = 175
Age (years) 1221 64.4 (7.6) 66.9 (7.9)** 68.3 (8.2) 70.7 (7.4)*** 73.0 (8.4) 69.9 (8.8)
Female, n 1221 203 (56) 66 (52) 108 (49) 172 (56) 12 (44) 96 (55)
Education (years) 1221 13.5 (3.7) 12.7 (4.0)* 10.6 (3.8) 10.8 (3.7) 8.5 (4.4) 10.6 (3.8)**
APOE ε4 carrier, n 1221 122 (33) 76 (60)*** 46 (21) 200 (65)*** 7 (26) 114 (65)***
Mean follow-up time (years) 758 2.3 (0.8) 2.5 (1.1) 2.2 (1.3) 2.2 (1.3) 1.7 (0.9) 2.2 (1.4)
MMSE score 1215 28.9 (1.1) 28.8 (1.2) 27.0 (2.3) 25.9 (2.7)*** 21.5 (5.4) 21.7 (4.6)
Memory delayed z-score 1049 0.1 (1.1) 0.0 (1.2) −0.9 (1.3) −1.4 (1.4)*** −2.2 (1.2) −2.4 (1.1)
Language z-score 1181 −0.2 (1.0) −0.1 (1.0) − 0.7 (1.2) − 1.0 (2.0) − 1.9 (1.2) − 2.3 (2.4)
Attention z-score 1128 0.3 (1.1) 0.2 (0.9) −1.0 (1.8) −1.0 (1.8) −2.1 (2.5) −2.1 (2.0)
Executive functioning z-score 976 0.3 (1.1) 0.1 (1.1) −0.9 (1.9) −1.4 (2.1)* −1.2 (2.5) −3.4 (2.8)*
Visuoconstruction z-score 664 0.2 (1.4) 0.2 (0.8) −0.3 (1.7) −0.4 (1.8) −2.1 (2.4) −1.3 (2.0)
Results are mean (standard deviation) for continuous variables or frequency (%) for dichotomous variables
Aβ amyloid-beta, AD Alzheimer’s disease, APOE apolipoprotein E, MCI mild cognitive impairment, MMSE Mini Mental State Examination
*p < 0.05 in comparison to Aβ– group
**p < 0.01in comparison to Aβ– group
***p < 0.001 in comparison to Aβ– group
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Table 4 and Fig. 2 show the effect of Aβ on MMSE
scores over time for each diagnostic group, adjusted for
demographics. At baseline, there is only a difference in
MMSE for the MCI group (p < 0.001). In the NC and MCI
groups, the Aβ+ individuals in the NC and MCI groups
decline at a faster rate than the Aβ– individuals (NC, p <
0.001; MCI, p < 0.001). For the demented subjects, Aβ did
not influence the rate of decline (Table 4, Fig. 2).
Discussion
The aim of the EMIF consortium is to enable the
reutilization of preexisting data including the finding and
assessment of relevant datasets and facilitation of their
interoperability and reuse. For the EMIF-AD component, a
major use-case objective has been to use the processes and
tools established in the consortium to generate a novel
cross-cohort data and sample collection for the discovery
and validation of biomarkers for use in clinical trials using
a multimodal and endophenotype design. The first results
presented in this report confirm the central roles of Aβ and
APOE ε4 in the pathogenesis of AD, which is consistent
with findings from other large cohorts [36, 37]. The mo-
lecular studies are ongoing and will be reported in future
publications.
AD is a complex and multifactorial disorder, which un-
derscores the need for multimodal studies with sufficient
statistical power [38]. To date these large studies are
scarce, especially those including subjects across the whole
clinical AD spectrum. To our knowledge, the only other
large-scale studies that collected plasma, DNA, CSF and
imaging material from individuals in various cognitive
stages are the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) [36] and the Australian Imaging, Biomarkers and
Lifestyle (AIBL) study of aging [37] studies. Since these
datasets are so unique, findings from these studies are
difficult to validate. The current study will not only be of
great additional value due to its explorative nature and
complementary laboaratory analyses, but also because
previous findings can be validated in a large-size cohort
with multimodal data. We collected a wide variety of clin-
ical variables including neuropsychological tests, comor-
bidities, medication use and psychiatric questionnaires.
All of the clinical data and results from the multimodal
wet-lab analyses will be stored on an online, secure data
platform (tranSMART). Research proposals can be sub-
mitted via the EMIF-AD Catalog (https://emif-catalo-
gue.eu) to work with these data, which require approval
from the EMIF-AD team and the data-owners.
Besides the major advantages, this study also has some
limitations. Currently, we do not have clinical follow-up
data for all subjects, as some centers are still in the process
of collecting these. However, these data may be added to
the database in the future. Also, the data, samples and scans
contributed to this study were collected at different centers
and were not collected using the same protocol, which will
lead to preanalytical variability. To limit this variability, the
samples were analyzed centrally and the clinical data were
harmonized using standardized values and dichotomous
variables.
Table 3 Number of subjects from different cohorts for each
modality by diagnosis
Cohort Diagnosis Clinical data Plasma DNA MRI CSF
Amsterdam NC 30 29 26 30 30
MCI 82 80 68 82 82
AD-type dementia 60 60 53 60 60
Antwerp MCI 103 100 101 50 103
AD-type dementia 46 47 46 0 46
DESCRIPA NC 12 12 8 5 12
MCI 17 17 12 9 17
EDAR NC 48 47 42 14 47
MCI 77 75 65 24 75
AD-type dementia 79 78 69 19 76
GAP NC 40 40 40 38 40
Gothenburg NC 49 48 – 48 –
MCI 46 44 – 46 –
IDIBAPS NC 76 77 – 40 –
MCI 27 27 – 14 –
AD-type dementia 17 16 – 14 –
Lausanne NC 12 12 12 12 12
MCI 28 28 28 27 28
Leuven NC 180 163 168 179 –
PharmaCog MCI 147 144 146 147 147
Sant Pau NC 45 45 45 – –
Total NC 492 473 341 366 141
MCI 527 515 420 399 452
AD-type dementia 202 201 168 100 182
Overall 1221 1189 929 865 775
CSF cerebrospinal fluid, DESCRIPA development of screening guidelines and
clinical criteria for predementia Alzheimer's disease, EDAR beta amyloid
oligomers in the early diagnosis of AD and as a marker for treatment reponse,
GAP gipuzkoa Alzheimer project, IDIBAPS institut d'investigacions biomèdiques
August Pi i Sunyer, MCI mild cognitive impairment, MRI magnetic resonance
imaging, NC normal cognition
Table 4 Effect of Aβ on MMSE scores over time by diagnostic
group
Diagnosis n Baseline p value Slope p value
NC 482 − 0.35 ± 0.20 0.170 − 0.60 ± 0.13 < 0.001
MCI 459 − 1.56 ± 0.24 < 0.001 − 0.60 ± 0.14 < 0.001
AD dementia 162 − 0.05 ± 1.05 0.965 − 0.21 ± 0.64 0.742
Numbers are linear mixed-model coefficients ± standard error, relative to the
Aβ– group, adjusted for age, gender and years of education
Aβ amyloid-beta, AD Alzheimer’s disease, MCI mild cognitive impairment,
MMSE Mini Mental State Examination, NC normal cognition
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Conclusion
The various complementary analyses conducted in
plasma, DNA and CSF and on MRI scans in a large-sized
cohort of individuals across the clinical AD spectrum
provide a unique opportunity to discover novel diagnostic
and prognostic markers, and will also increase knowledge
into the AD pathophysiology, which is required for the
development of novel therapeutic interventions.
Additional files
Additional file 1: Table S1. Diagnostic criteria per cohort. Cohorts,
countries, number of subjects and diagnostic criteria used for NC, MCI
and AD dementia (DOCX 90 kb)
Additional file 2: Table S2. Number of subjects per test by cognitive
domain at baseline. Number of subjects per test and norms used in
domains of global cognition, memory, language, attention, executive
functioning and visuoconstruction (DOCX 90 kb)
Additional file 3: Table S3. Biomarker protocol information for each
cohort. Protocol information for PET, CSF and plasma biomarker
collection (DOCX 100 kb)
Additional file 4: Table S4. Ethical approval committee of each center.
Ethical approval committees in each of the participating centers
(DOCX 109 kb)
Abbreviations
AD: Alzheimer’s disease; ADP: Affiliated data provider; APOE: Apolipoprotein
E; Aβ: Amyloid-beta; CSF: Cerebrospinal fluid; IMI: Innovative Medicine
Initiative; MCI: Mild cognitive impairment; MMSE: Mini Mental State
Examination; MRI: Magnetic resonance imaging; NC: Normal cognition;
NFL: Neurofilament light; Ng: Neurogranin; PET: Positron emission
tomography
Acknowledgements
The authors would like to thank all people involved in data and sample
collection and/or logistics across the different centers, and in particular:
Marije Benedictus, Wiesje van de Flier, Charlotte Teunissen, Ellen De Roeck,
Naomi De Roeck, Ellis Niemantsverdriet, Charisse Somers, Babette Reijs,
Andrea Izagirre Otaegi, Mirian Ecay Torres, Sindre Rolstad, Eva Bringman,
Domilé Tautvydaité, Barbara Moullet, Charlotte Evenepoel, Isabelle Cleynen,
Bea Bosch, Daniel Alcolea Rodriguez, Moira Marizzoni, Alberto Redolfi and
Paolo Bosco.
Funding
The present study was conducted as part of the EMIF-AD project which has
received support from the Innovative Medicines Initiative Joint Undertaking
under EMIF grant agreement n° 115372, the resources of which are composed
of financial contribution from the European Union’s Seventh Framework
Program (FP7/2007–2013) and EFPIA companies’ in kind contribution. The
DESCRIPA study was funded by the European Commission within the 5th
framework program (QLRT-2001-2455). The EDAR study was funded by the
European Commission within the 5th framework program (contract # 37670).
The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek
(grant numbers #11020, #13007 and #15005). RV is a senior clinical investigator
of the Flemish Research Foundation (FWO). The San Sebastian GAP study is
partially funded by the Department of Health of the Basque Government
(allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The authors acknowledge
the contribution of the personnel of the Genomic Service Facility at the VIB-U
Antwerp Center for Molecular Neurology. The research at VIB-CMN is funded
in part by the University of Antwerp Research Fund.
Availability of data and materials
The dataset presented in the current study is available upon request and
after approval of each data provider, via the EMIF-AD platform (https://emif-
catalogue.eu; http://www.emif.eu/about/emif-ad).
Authors’ contributions
IB contributed to study coordination, data management and statistical
analyses, and wrote the manuscript. SV contributed to study coordination
and wrote the manuscript. RV, PS, SE, GF, JLM, AW, AL, JP and PM-L
contributed to data and sample collection. AB was responsible for plasma
proteomic analyses. RD was responsible for multimodal analyses. CL-Q
was responsible for plasma metabolomics analyses. KS and CVB were
responsible for genetics (exome sequencing). LB was responsible for
Fig. 2 MMSE scores over time by Aβ status and diagnosis. Mean scores and 95% confidence intervals of MMSE over time for three diagnostic
groups and by Aβ status, adjusted for demographics. Solid lines represent Aβ– groups, dashed lines represent Aβ+ groups. Aβ amyloid-beta, AD
Alzheimer’s disease, MCI mild cognitive impairment, MMSE Mini Mental State Examination, NC normal cognition
Bos et al. Alzheimer's Research & Therapy  (2018) 10:64 Page 7 of 9
genetics (DNA extraction and QC, genome-wide SNP genotyping and
methylation profiling). MtK and FB were responsible for MRI analyses.
HZ was responsible for CSF analyses. SL and JS contributed to study
design and study coordination. PJV contributed to study design and
study coordination, and wrote the manuscript. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Written informed consent was obtained from all participants before inclusion
in the study. The medical ethics committee at each site approved the study
(Additional file 4: Table S4).
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Alzheimer Centrum Limburg, Maastricht University, Maastricht, the
Netherlands. 2University Hospital Leuven, Leuven, Belgium. 3Laboratory for
Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven,
Belgium. 4Alzheimer Center and Department of Neurology, VU University
Medical Center, Amsterdam, the Netherlands. 5Reference Center for
Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp,
Belgium. 6Department of Neurology and Memory Clinic, Hospital Network
Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium. 7University
of Antwerp, Antwerp, Belgium. 8University of Geneva, Geneva, Switzerland.
9IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
10Alzheimer’s Disease & Other Cognitive Disorders Unit, Hospital
Clínic—IDIBAPS, Barcelona, Spain. 11Barcelona Beta Brain Research Center,
Fundació Pasqual Maragall, Barcelona, Spain. 12Institute of Neuroscience and
Physiology, Moelndal, Sweden. 13Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain. 14Geriatric Psychiatry, Department of Mental Health and
Psychiatry, Geneva University Hospitals, Geneva, Switzerland. 15Department of
Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland. 16Center
for Research and Advanced Therapies, CITA—Alzheimer Foundation, San
Sebastian, Spain. 17University of Oxford, Oxford, UK. 18King’s College London,
London, UK. 19NIHR Biomedical Research Centre for Mental Health and
Biomedical Research Unit for Dementia at South London and Maudsley NHS
Foundation, London, UK. 20Farr Institute of Health Informatics Research, UCL
Institute of Health Informatics, University College London, London, UK.
21NIHR University College London Hospitals Biomedical Research Centre,
London, UK. 22Neurodegenerative Brain Diseases Group, VIB—Department of
Molecular Genetics, Antwerp, Belgium. 23Institute Born-Bunge, University of
Antwerp, Antwerp, Belgium. 24Lübeck Interdisciplinary Platform for Genome
Analytics, University of Lübeck, Lübeck, Germany. 25School of Public Health,
Imperial College London, London, UK. 26Department of Psychology,
University of Oslo, Oslo, Norway. 27Department of Radiology and Nuclear
Medicine, VU University Medical Center, Amsterdam, the Netherlands.
28Department of Psychiatry and Neurochemistry, University of Gothenburg,
Mölndal, Sweden. 29Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital, Mölndal, Sweden. 30Department of Molecular
Neuroscience, UCL Institute of Neurology, London, UK. 31UK Dementia
Research Institute, London, UK. 32Experimental Medicine, Janssen
Pharmaceutical Companies, Beerse, Belgium. 33Department of Psychiatry &
Neuropsychology, School for Mental Health and Neuroscience, Alzheimer
Center Limburg, Maastricht University, Universiteitssingel 40, Box 34, P.O. Box
616, 6200, MD, Maastricht, the Netherlands.
Received: 10 October 2017 Accepted: 8 June 2018
References
1. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw
LM, Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological
processes in Alzheimer's disease: an updated hypothetical model of
dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS,
Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly
inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795–804.
3. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's
disease: implications for prevention trials. Neuron. 2014;84(3):608–22.
4. Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P,
Salter H, Potter WZ, Sperling RS, Bateman RJ, et al. Revolutionizing
Alzheimer's disease and clinical trials through biomarkers. Alzheimers
Dement (Amst). 2015;1(4):412–9.
5. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K,
Bokde AL, Jessen F, Hoessler YC, et al. Biomarkers for Alzheimer's
disease: academic, industry and regulatory perspectives. Nat Rev Drug
Discov. 2010;9(7):560–74.
6. Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chetelat G. Amyloid PET
in clinical practice: its place in the multidimensional space of Alzheimer's
disease. Neuroimage Clin. 2013;2:497–511.
7. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S,
Van der Flier WM. Alzheimer's disease. Lancet. 2016;388(10043):505–17.
8. Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH,
Teunissen CE, Scheltens P, van der Flier WM. Diagnostic impact of CSF
biomarkers for Alzheimer's disease in a tertiary memory clinic.
Alzheimers Dement. 2015;11(5):523–32.
9. Rathore S, Habes M, Iftikhar MA, Shacklett A, Davatzikos C. A review on
neuroimaging-based classification studies and associated feature
extraction methods for Alzheimer's disease and its prodromal stages.
NeuroImage. 2017;155:530–48.
10. Laske C. Blood-based biomarkers in Alzheimer disease: where are we now
and where have we to go? JAMA Neurol. 2013;70(1):133.
11. Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone
S, Mielke MM, O'Bryant S, Sarasa M, Sjogren M, et al. Developing novel
blood-based biomarkers for Alzheimer's disease. Alzheimers Dement.
2014;10(1):109–14.
12. Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma,
serum and blood—conceptual and practical problems. Alzheimers Res
Ther. 2013;5(2):10.
13. Baird AL, Westwood S, Lovestone S. Blood-based proteomic biomarkers of
Alzheimer's disease pathology. Front Neurol. 2015;6:236.
14. Reijs BLR, Ramakers I, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M,
Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, et al. Relation
of odor identification with Alzheimer's disease markers in cerebrospinal fluid
and cognition. J Alzheimers Dis. 2017;60(3):1025–34.
15. Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-
Faz D, Cordone S, Didic M, Farotti L, et al. Clinical and biomarker profiling of
prodromal Alzheimer's disease in workpackage 5 of the Innovative
Medicines Initiative PharmaCog project: a 'European ADNI study. J Intern
Med. 2016;279(6):576–91.
16. Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, Frolich L,
Hampel H, Jolles J, Jones R, et al. Development of screening guidelines and
clinical criteria for predementia Alzheimer's disease. The DESCRIPA study.
Neuroepidemiology. 2008;30(4):254–65.
17. Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck
N, De Roeck E, De Vil B, Cras P, Martin JJ, et al. A decade of
cerebrospinal fluid biomarkers for Alzheimer's disease in Belgium. J
Alzheimers Dis. 2016;54(1):383–95.
18. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH,
Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, et al.
Optimizing patient care and research: the Amsterdam Dementia Cohort.
J Alzheimers Dis. 2014;41(1):313–27.
19. Alcolea D, Carmona-Iragui M, Suarez-Calvet M, Sanchez-Saudinos MB, Sala I,
Anton-Aguirre S, Blesa R, Clarimon J, Fortea J, Lleo A. Relationship between
beta-Secretase, inflammation and core cerebrospinal fluid biomarkers for
Alzheimer's disease. J Alzheimers Dis. 2014;42(1):157–67.
20. Fortea J, Sala-Llonch R, Bartres-Faz D, Bosch B, Llado A, Bargallo N,
Molinuevo JL, Sanchez-Valle R. Increased cortical thickness and caudate
volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis.
2010;22(3):909–22.
21. Adamczuk K, Schaeverbeke J, Nelissen N, Neyens V, Vandenbulcke M,
Goffin K, Lilja J, Hilven K, Dupont P, Van Laere K, et al. Amyloid
imaging in cognitively normal older adults: comparison between (18)F-
flutemetamol and (11)C-Pittsburgh compound B. Eur J Nucl Med Mol
Imaging. 2016;43(1):142–51.
Bos et al. Alzheimer's Research & Therapy  (2018) 10:64 Page 8 of 9
22. Estanga A, Ecay-Torres M, Ibanez A, Izagirre A, Villanua J, Garcia-Sebastian M,
Iglesias Gaspar MT, Otaegui-Arrazola A, Iriondo A, Clerigue M, et al.
Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and
cognition. Neurobiol Aging. 2017;50:144–51.
23. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Ohrfelt A,
Stalhammar J, Eckerstrom M, Carlsson M, Olsson E, et al. Alzheimer's
disease—subcortical vascular disease spectrum in a hospital-based setting:
overview of results from the Gothenburg MCI and dementia studies. J
Cereb Blood Flow Metab. 2016;36(1):95–113.
24. Tautvydaite D, Kukreja D, Antonietti JP, Henry H, von Gunten A, Popp J.
Interaction between personality traits and cerebrospinal fluid biomarkers of
Alzheimer's disease pathology modulates cognitive performance.
Alzheimers Res Ther. 2017;9(1):6.
25. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring
rules. Neurology. 1993;43(11):2412–4.
26. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration
Scale for assessment of primary degenerative dementia. Am J
Psychiatry. 1982;139(9):1136–9.
27. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern
Med. 2004;256(3):183–94.
28. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO,
Nordberg A, Backman L, Albert M, Almkvist O, et al. Mild cognitive
impairment—beyond controversies, towards a consensus: report of the
International Working Group on Mild Cognitive Impairment. J Intern
Med. 2004;256(3):240–6.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work
group under the auspices of Department of Health and Human Services
Task Force on Alzheimer's disease. Neurology. 1984;34(7):939–44.
30. Scheufele E, Aronzon D, Coopersmith R, McDuffie MT, Kapoor M, Uhrich CA,
Avitabile JE, Liu J, Housman D, Palchuk MB. tranSMART: an open source
knowledge management and high content data analytics platform. AMIA Jt
Summits Transl Sci Proc. 2014;2014:96–101.
31. Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R,
Westman E, Simmons A, Dobson R, Sattlecker M, et al. Plasma proteins
predict conversion to dementia from prodromal disease. Alzheimers
Dement. 2014;10(6):799–807. e792
32. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P,
Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal
lobes on MRI in “probable” Alzheimer’s disease and normal ageing:
diagnostic value and neuropsychological correlates. J Neurol Neurosurg
Psychiatry. 1992;55(10):967–72.
33. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P.
Inter- and intraobserver reproducibility of cerebral atrophy assessment on
MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268–72.
34. Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox
N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy
development of a MRI rating scale. Eur Radiol. 2011;21(12):2618–25.
35. Redolfi A, Bosco P, Manset D, Frisoni GB. Brain investigation and brain
conceptualization. Funct Neurol. 2013;28(3):175–90.
36. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski
JQ, Toga AW, Beckett L. The Alzheimer's Disease Neuroimaging Initiative.
Neuroimaging Clin N Am. 2005;15(4):869–77. xi–xii.
37. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT,
Lenzo N, Martins RN, Maruff P, et al. The Australian Imaging, Biomarkers and
Lifestyle (AIBL) study of aging: methodology and baseline characteristics of
1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int
Psychogeriatr. 2009;21(4):672–87.
38. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis
and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916–22.
Bos et al. Alzheimer's Research & Therapy  (2018) 10:64 Page 9 of 9
